Day One Biopharmaceuticals (DAWN) News Today → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free DAWN Stock Alerts $15.19 -1.45 (-8.71%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineDay One Biopharmaceuticals (NASDAQ:DAWN) Receives "Outperform" Rating from Wedbushamericanbankingnews.com - April 25 at 6:47 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Sees Unusually-High Trading Volume Following Analyst Upgradeamericanbankingnews.com - April 25 at 2:02 AMDay One slips despite Ojemda approval as BofA says label “not a home run”msn.com - April 24 at 7:17 PMDay One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fairseekingalpha.com - April 24 at 2:15 PMDay One Biopharmaceuticals' (DAWN) "Outperform" Rating Reiterated at Wedbushmarketbeat.com - April 24 at 2:13 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume Increase Following Analyst Upgrademarketbeat.com - April 24 at 11:01 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Price Target Raised to $33.00 at Needham & Company LLCmarketbeat.com - April 24 at 7:29 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Up 12.2% After Analyst Upgradeamericanbankingnews.com - April 24 at 2:07 AMBuy Rating on Day One Biopharmaceuticals Amid FDA Approval and Strong Market Prospectsmarkets.businessinsider.com - April 23 at 11:13 PMBuy Rating Affirmed for Day One Biopharmaceuticals Following FDA Approval of Ojemdamarkets.businessinsider.com - April 23 at 11:13 PMDay One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumorfinance.yahoo.com - April 23 at 6:12 PMDay One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumorglobenewswire.com - April 23 at 3:56 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 12.2% on Analyst Upgrademarketbeat.com - April 23 at 2:37 PMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 Sharesinsidertrades.com - April 23 at 4:24 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Price Target Increased to $36.00 by Analysts at JPMorgan Chase & Co.americanbankingnews.com - April 23 at 3:48 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Analyst Upgradeamericanbankingnews.com - April 23 at 1:06 AMBuy Rating Affirmed for Day One Biopharmaceuticals on Strong Tovorafenib Prospects and Market Impactmarkets.businessinsider.com - April 22 at 10:07 PMInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 10,000 Shares of Stockmarketbeat.com - April 22 at 9:20 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up Following Analyst Upgrademarketbeat.com - April 22 at 11:39 AMDay One Biopharmaceuticals (NASDAQ:DAWN) PT Raised to $36.00 at JPMorgan Chase & Co.marketbeat.com - April 22 at 11:00 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 4.7%americanbankingnews.com - April 21 at 5:46 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 4.7% marketbeat.com - April 19 at 2:56 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Sees Strong Trading Volumemarketbeat.com - April 18 at 4:55 PMShort Interest in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Declines By 6.6%americanbankingnews.com - April 18 at 5:10 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Moderate Buy" by Brokeragesamericanbankingnews.com - April 17 at 2:26 AMAnalysts Are Bullish on These Healthcare Stocks: OptimizeRx (OPRX), Day One Biopharmaceuticals (DAWN)markets.businessinsider.com - April 16 at 6:18 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Trading 3.8% Higher marketbeat.com - April 16 at 2:01 PMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Down 6.6% in Marchmarketbeat.com - April 16 at 1:40 PMBuy Rating on Day One Biopharmaceuticals Ahead of Tovorafenib PDUFA Date and Potential for Market Disruptionmarkets.businessinsider.com - April 10 at 8:30 AMVanguard Group Inc. Grows Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)marketbeat.com - April 8 at 4:09 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 3.4%marketbeat.com - April 4 at 5:28 PMDay One Biopharmaceuticals Inc DAWNmorningstar.com - April 4 at 1:27 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Trading 6.9% Higher marketbeat.com - March 28 at 7:27 PMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $160,100.00 in Stockmarketbeat.com - March 26 at 9:17 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX)markets.businessinsider.com - March 26 at 10:39 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Earns Overweight Rating from Piper Sandlermarketbeat.com - March 26 at 8:25 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 3.8%marketbeat.com - March 22 at 5:05 PMDAWN Jul 2024 17.500 callfinance.yahoo.com - March 17 at 3:12 PMWalleye Capital LLC Makes New $3.40 Million Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)marketbeat.com - March 16 at 4:53 AMCompanies Like Day One Biopharmaceuticals (NASDAQ:DAWN) Are In A Position To Invest In Growthfinance.yahoo.com - March 15 at 12:53 PMPolar Capital Holdings Plc Has $23.74 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)marketbeat.com - March 12 at 10:45 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by TimesSquare Capital Management LLCmarketbeat.com - March 11 at 9:49 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Adage Capital Partners GP L.L.C.marketbeat.com - March 9 at 6:35 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down to $16.68marketbeat.com - March 6 at 1:54 PMmarketbeat.com - March 6 at 9:36 AMTrexquant Investment LP Invests $1.20 Million in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)marketbeat.com - March 5 at 7:54 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Charles Schwab Investment Management Inc.marketbeat.com - March 4 at 4:25 AMBraidwell LP Raises Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)marketbeat.com - March 1 at 10:18 AMAnalysts Are Bullish on Top Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)markets.businessinsider.com - February 29 at 2:06 PMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) to Post Q1 2024 Earnings of ($0.71) Per Share, Capital One Financial Forecastsmarketbeat.com - February 29 at 8:22 AM Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… DAWN Media Mentions By Week DAWN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DAWN News Sentiment▼0.740.43▲Average Medical News Sentiment DAWN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DAWN Articles This Week▼292▲DAWN Articles Average Week Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Pacira BioSciences News Today Verona Pharma News Today Ironwood Pharmaceuticals News Today Kiniksa Pharmaceuticals News Today Deciphera Pharmaceuticals News Today Gyre Therapeutics News Today AbCellera Biologics News Today ANI Pharmaceuticals News Today Morphic News Today Collegium Pharmaceutical News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DAWN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
